Typically, Big Pharma analyst days aren’t known for being particularly newsy. But that certainly wasn’t the case at Merck & Co. Inc. ’s annual event, held December 9 at the firm’s Whitehouse Statio
Perhaps, if they wanted to. Luckily, they’re not the only product-hungry firms. Overall, dealmaking will pick up because more of the deals that would otherwise have fallen apart over price will now ge
The word from JP Morgan: Big Pharma goes biotech both to trim infrastructure and—ironically—re-start its traditional me-better approach. By Roger Longman Biotech investors see their best exits through